New study tracks bleeding risks in kids taking blood thinners

NCT ID NCT06278051

Completed Knowledge-focused Sponsor: Bayer Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at data from children under 18 in Japan who were prescribed either rivaroxaban or warfarin for blood clots. Researchers want to see how often major bleeding happens in real-world use. No new treatments are given—only existing medical records are reviewed.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: rivaroxaban (Xarelto)
What this could lead to: If successful, this study could provide a clearer picture of bleeding risks in children taking rivaroxaban for blood clots, helping doctors make safer prescribing decisions.
What could go wrong: This is an observational study that only looks at existing data, so it cannot prove cause and effect. Results may be limited by the quality of the records and may not apply to all children.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VENOUS THROMBOEMBOLISM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

venous thromboembolism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

VENOUS THROMBOEMBOLISM

Contacts and locations

Locations

Bayer

Osaka, 530-0001, Japan
Many facilities

Multiple Locations, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.